HUE066627T2 - Mátrix metalloproteináz (MMP) inhibitorok és azok alkalmazási módszerei - Google Patents

Mátrix metalloproteináz (MMP) inhibitorok és azok alkalmazási módszerei

Info

Publication number
HUE066627T2
HUE066627T2 HUE19731374A HUE19731374A HUE066627T2 HU E066627 T2 HUE066627 T2 HU E066627T2 HU E19731374 A HUE19731374 A HU E19731374A HU E19731374 A HUE19731374 A HU E19731374A HU E066627 T2 HUE066627 T2 HU E066627T2
Authority
HU
Hungary
Prior art keywords
mmp
inhibitors
methods
matrix metalloproteinase
metalloproteinase
Prior art date
Application number
HUE19731374A
Other languages
English (en)
Hungarian (hu)
Inventor
Wenjin Yang
Original Assignee
Foresee Pharmaceuticals Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foresee Pharmaceuticals Usa Inc filed Critical Foresee Pharmaceuticals Usa Inc
Publication of HUE066627T2 publication Critical patent/HUE066627T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE19731374A 2018-05-15 2019-05-14 Mátrix metalloproteináz (MMP) inhibitorok és azok alkalmazási módszerei HUE066627T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862671753P 2018-05-15 2018-05-15

Publications (1)

Publication Number Publication Date
HUE066627T2 true HUE066627T2 (hu) 2024-08-28

Family

ID=66690981

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE19731374A HUE066627T2 (hu) 2018-05-15 2019-05-14 Mátrix metalloproteináz (MMP) inhibitorok és azok alkalmazási módszerei
HUE19728197A HUE066619T2 (hu) 2018-05-15 2019-05-14 Mátrix metalloproteináz (MMP) inhibitorok és azok alkalmazási módszerei

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE19728197A HUE066619T2 (hu) 2018-05-15 2019-05-14 Mátrix metalloproteináz (MMP) inhibitorok és azok alkalmazási módszerei

Country Status (20)

Country Link
US (6) US11739080B2 (cg-RX-API-DMAC7.html)
EP (4) EP3793992B1 (cg-RX-API-DMAC7.html)
JP (4) JP7343571B2 (cg-RX-API-DMAC7.html)
KR (3) KR102861502B1 (cg-RX-API-DMAC7.html)
CN (3) CN119462623A (cg-RX-API-DMAC7.html)
AU (3) AU2019270975B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020023269A2 (cg-RX-API-DMAC7.html)
CA (2) CA3100319A1 (cg-RX-API-DMAC7.html)
DK (2) DK3793995T3 (cg-RX-API-DMAC7.html)
ES (2) ES2984594T3 (cg-RX-API-DMAC7.html)
FI (2) FI3793992T3 (cg-RX-API-DMAC7.html)
HU (2) HUE066627T2 (cg-RX-API-DMAC7.html)
LT (1) LT3793995T (cg-RX-API-DMAC7.html)
MY (1) MY199200A (cg-RX-API-DMAC7.html)
PL (1) PL3793995T3 (cg-RX-API-DMAC7.html)
PT (2) PT3793995T (cg-RX-API-DMAC7.html)
SG (2) SG11202011318QA (cg-RX-API-DMAC7.html)
SI (1) SI3793995T1 (cg-RX-API-DMAC7.html)
TW (3) TWI827601B (cg-RX-API-DMAC7.html)
WO (2) WO2019222154A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532102B2 (en) * 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
SG11202011318QA (en) * 2018-05-15 2020-12-30 Foresee Pharmaceuticals Usa Inc Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
DK4058437T3 (da) 2019-11-14 2025-01-20 Foresee Pharmaceuticals Usa Inc Matrix-metalloproteinase-(MMP)-inhibitorer og fremgangsmåder til anvendelse heraf
JP2024520818A (ja) * 2021-06-08 2024-05-24 フォアシー ファーマシューティカルズ カンパニー リミテッド 急性呼吸促迫症候群を処置するためのmmp阻害薬の使用
KR20240019265A (ko) * 2021-06-08 2024-02-14 포시 파마슈티컬스 컴퍼니 리미티드 Mmp-12 억제제의 안전한 투여
EP4198033A1 (en) 2021-12-14 2023-06-21 Basf Se Heterocyclic compounds for the control of invertebrate pests
WO2023110473A1 (en) 2021-12-14 2023-06-22 Basf Se Heterocyclic compounds for the control of invertebrate pests

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2482618A1 (fr) 1980-05-16 1981-11-20 Inst Corps Gras Iterg Procede de conjugaison catalytique de corps gras polyinsatures, produits obtenus et application
AU1817700A (en) 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6352976B1 (en) 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
AU4882101A (en) 2000-04-28 2001-11-12 Shionogi & Co., Ltd. Mmp-12 inhibitors
SE0100903D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
MXPA03008180A (es) * 2001-03-15 2003-12-12 Astrazeneca Ab Inhibidores de metaloproteinasa.
ATE445400T1 (de) 2001-05-25 2009-10-15 Bristol Myers Squibb Co Hydantion-derivate als hemmer von matrix- metalloproteinasen
EP1394159A1 (fr) 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
WO2004033632A2 (en) * 2002-10-04 2004-04-22 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
US7132432B2 (en) * 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
ES2364068T3 (es) * 2004-08-19 2011-08-24 Quest Pharmaceutical Services 5-[3-(4-benciloxifeniltio)-fur-2-il]-imidazolin-2,4-diona y sus análogos como inhibidores de macrófago elastasa.
JP5357365B1 (ja) 2011-12-21 2013-12-04 パナソニック株式会社 データ処理装置、データ送信装置、データ処理システム、データ処理方法、及び、データ送信方法
SG11202011318QA (en) * 2018-05-15 2020-12-30 Foresee Pharmaceuticals Usa Inc Matrix metalloproteinase (mmp) inhibitors and methods of use thereof

Also Published As

Publication number Publication date
EP3793995B1 (en) 2024-01-10
US20250115590A1 (en) 2025-04-10
DK3793995T3 (da) 2024-04-08
PT3793992T (pt) 2024-05-13
US10851089B2 (en) 2020-12-01
EP4349332A3 (en) 2024-05-15
LT3793995T (lt) 2024-04-25
DK3793992T3 (da) 2024-04-08
EP3793992B1 (en) 2024-01-10
CN112424192B (zh) 2024-11-26
TW202400584A (zh) 2024-01-01
AU2019270975B2 (en) 2023-12-14
TW202003493A (zh) 2020-01-16
US20210214340A1 (en) 2021-07-15
CN119462623A (zh) 2025-02-18
FI3793995T3 (fi) 2024-04-17
TW202002975A (zh) 2020-01-16
KR20250021604A (ko) 2025-02-13
US12258335B1 (en) 2025-03-25
FI3793992T3 (fi) 2024-04-17
US20190352288A1 (en) 2019-11-21
EP3793992A1 (en) 2021-03-24
ES2978192T3 (es) 2024-09-06
JP2021523240A (ja) 2021-09-02
AU2024200323A1 (en) 2024-02-01
KR20210020897A (ko) 2021-02-24
MY199200A (en) 2023-10-19
AU2019269409B2 (en) 2023-11-23
JP7343571B2 (ja) 2023-09-12
KR20210020011A (ko) 2021-02-23
US11739080B2 (en) 2023-08-29
EP4335499A3 (en) 2024-05-15
CN112424186A (zh) 2021-02-26
US20240018131A1 (en) 2024-01-18
SG11202011318QA (en) 2020-12-30
TWI798435B (zh) 2023-04-11
PT3793995T (pt) 2024-05-02
SI3793995T1 (sl) 2024-05-31
JP7656669B2 (ja) 2025-04-03
US20190352287A1 (en) 2019-11-21
TWI895726B (zh) 2025-09-01
US12215096B2 (en) 2025-02-04
CA3100320A1 (en) 2019-11-21
WO2019222157A1 (en) 2019-11-21
JP7344959B2 (ja) 2023-09-14
KR102861502B1 (ko) 2025-09-18
PL3793995T3 (pl) 2024-05-06
AU2019269409A1 (en) 2021-01-07
KR102761591B1 (ko) 2025-01-31
ES2984594T3 (es) 2024-10-30
EP4349332A2 (en) 2024-04-10
TWI827601B (zh) 2024-01-01
HUE066619T2 (hu) 2024-08-28
CA3100319A1 (en) 2019-11-21
CN112424192A (zh) 2021-02-26
WO2019222154A1 (en) 2019-11-21
EP4335499A2 (en) 2024-03-13
AU2024200323B2 (en) 2025-06-05
JP2023164905A (ja) 2023-11-14
JP2023164924A (ja) 2023-11-14
EP3793995A1 (en) 2021-03-24
BR112020023269A2 (pt) 2021-02-23
SG11202011316RA (en) 2020-12-30
EP4349332B1 (en) 2026-07-15
AU2019270975A1 (en) 2021-01-07
JP2021523241A (ja) 2021-09-02

Similar Documents

Publication Publication Date Title
SG11202011316RA (en) Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
IL287768A (en) Kcnt1 inhibitors and methods of use
IL287751A (en) Kcnt1 inhibitors and methods of use
PT3911648T (pt) 6¿-[[(1s,3s)-3-[[5-(difluorometoxi)-2-pirimidinil]amino]ciclopentil]amino][1(2h),3¿-bipiridina]-2-ona como inibidor de pcsk9 e seus métodos de utilização
IL283592A (en) Inhibitors of apol1 and methods of using same
DK3870579T3 (da) Tyk2-inhibitorer og anvendelser deraf
ZA202407941B (en) Arginase inhibitors and methods of use thereof
IL279475A (en) Actonucleotidase inhibitors and methods of using them
IL287973A (en) acss2 inhibitors and methods of their use
IL282350A (en) Bernani-RGMC inhibitors and their use
IL274504A (en) 2ACSS inhibitors and methods of their use
IL278989A (en) MASP-2 suppressors and methods of using them
IL280924A (en) Arginase inhibitors and methods of using them
IL286485A (en) Pi4-kinase inhibitors and methods of using the same
HUE069818T2 (hu) Mátrix metalloproteináz (MMP) inhibitorok és azok alkalmazási módszerei
HK40049706A (en) Ectonucleotidase inhibitors and methods of use thereof
HK40050318A (en) Masp-2 inhibitors and methods of use
HK40036932A (en) Nek inhibitors and methods of use